Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma

Figure 2

ML120B synergizes with the microtubule inhibitor, vincristine. Cell viability was measured by trypan blue exclusion assay over a 72 h incubation period, Mean and standard deviation (SD). WSU-FSCCL cells were exposed to each agent at the indicated concentrations for 72 h or pretreated with ML120B (20 μM) for 60 minutes followed by (A) cyclophosphamide (5.84 pM), (B) doxorubicin (1.5 pM), or (C) vincristine (260 pM, or 520 pM). D. Student t-test was used to calculate the values for combinational treatments. E. Synergy was calculated using CalcuSyn V2; CI < 0.9 indicates synergy. ML120B:vincristine synergized at all concentrations used. F. Combinational index (CI) curve according to Chou-Talalay method (reference 24) used to determine synergy between ML120B and vincristine. A ratio of <0.9 indicates synergy. Abbreviations used: M = ML120B, C = cyclophosphamide monohydrate, H = doxorubicin, V = vincristine, CTR = control (vehicle-treated cells).

Back to article page